ProKidney Corp.’s Post

This TDAPA approval is a big deal. When a new drug gets FDA approval, it takes a lot of time and effort to get providers to use it. But here it’s totally different ball game. Starting 1st of July CMS will pay 249.99 USD per vial of Defencath. A dialysis session needs 2 vials and so, 500 USD per session of dialysis. Patients get dialysis 3 times a week and so, 288 vials per patient per year/ 72000 USD per patient per year. The dialysis provider such as DaVita etc. will get part of this payment and CorMedix will get the rest. Let’s say the dialysis provider gets 150 USD per vial and CorMedix gets 100 USD per vial. That’s big money for the dialysis providers and so the major dialysis providers are eagerly waiting for July 1st to start using Defencath. The company estimates 37 to 46 million vials just in the outpatient setting per year. That’s like up to 4 billion USD per year revenue just from outpatient. Inpatient will be additional. Looking at 4 billion USD revenue in 2025. That means a share price of about 75 USD per share. Counting inpatient revenue: 100 USD per share. Guaranteed full CMS reimbursement for first 2 years and then 65% of ASP for 3 years and after that dialysis bundle. Easy 2000% gain in 12 months!

What the short sellers are relying on is that the company will need another stock offering in the near future. That is pretty much the only way short Sellers can succeed in what they are doing. But can that happen? It can happen only if there are no contracts with the 2 big dialysis companies. It is extremely unlikely that the 2 big dialysis companies will not sign contracts in the next few weeks. There is 99% chance that the 2 big dialysis companies will sign contracts with CorMedix this month. They are going to make money so it does not make any sense that they will lose this opportunity. But apparently the market is not realizing this at this time. After all we are tiny company with little to no communication with investors on the wall street. Almost 10 million shares of CRMD are short at this time. What will help is announcement of contracts and then big revenue. That is going to happen very soon. If the stock price still stays low despite revenue, the company will have the option to buy back the shares. So even though this market does not work for the retail investors, yet short sellers are going to have an extremely bad day very soon!! We have a great CEO and he will make it happen!

For patient’s sake - we must keep reminding ourselves that ‘approval’ doesn’t equal ‘patient access...’ Yes, it is of course a crucial step in the development pathway & yes, it is a milestone worth celebrating for all the ‘blood, sweat & tears’ that go into the journey that far but there is still much ground which exists between approval and access that needs to be bridged to enable patients to benefit! Lately, we’ve seen a breakthrough in the # genetherapy space with the recent approvals of Lyfgenia and Casgevy by #Bluebirdbio and #Vertex, respectively, for the treatment of sickle cell disease (SCD)… #patientaccess will now be driven by the ability of each company being able to successfully negotiate deals with payors and insurers globally. I hope that they are successful for the sake of the many sickle cell patients worldwide that will benefit from these marvelous innovations! #patientaccess #sicklecelldisease #raredisease #genetherapy #iconplc

HA130 resin hemoperfusion cartridge is of relatively specific recognition and adsorption capacity to the macromolecular uremic toxins resulting from long-term hemodialysis and hemofiltration in blood of end-stage renal disease (ESRD) patients. In clinic, HD+HP treatment by association of hemodialysis (HD) & hemoperfusion(HP) could clear various uremic toxins in ESRD patients, decrease morbidity of complications in long-term and short-term, prolong life span and improve life quality. The product is hereinafter named as hemoperfusion cartridge for short. #seeb_diyalisis_center#jafron#HA130#Hemoperfusion#muscat#oman#🇴🇲

This technical report details methods for performing dialytic therapies, such as intermittent hemodialysis (iHD) and continuous renal replacement therapy (CRRT), safely and effectively through an ECMO circuit, eliminating the need for a separate dialysis catheter in patients with acute kidney injury (AKI) and end-stage renal disease (ESRD). #CardioHelp #CRRT #ECMO #Hemodialysis #Nautilus

The outcomes of PCI in diabetics have been suboptimal in current generational DES and have been unclear in DCB . The landmark EASTBOURNE @ 3,000 patient study, is the Worlds Largest DCB experiance in real world population using the Magic Touch SCB , viz Novel Next generational & Worlds 1st CE commercialized Sirolimus DCB. We are thankful to Dr Bernardo Cortese , Dr Antonio Colombo and the many other Globally renonwned Investigators of EASTBOURNE study. The Now published Diabetic cohort of 864 Patients with remarkable results with Magic Touch SCB having no significant increase in TLR vs Non Diabetic and more over the diabetic status , did not affect device performance in terms of TLR in both de-novo lesions & ISR . The expanding evidence of the US FDA breakthrough designated device continues to extend its favourable treatement effects accross complex occlusive vascular diseases with real world use in over 80 countries Worldwide- Confidence Inspired by Real World Use # Gamechanger Technologies # Largest & Longest Studies Clinical Program of over 23 k patients # US FDA breakthrough Designation # over 100k patients treated globally spanning over 80 countries

Which is the role of DCB in diabetic patients? Published today the subanalysis of the #EastbourneStudy in diabetic patients, by Gianluca Caiazzo Angelo Oliva et Al. #CardiovascularDiabetology Fondazione Ricerca e Innovazione Cardiovascolare DCB ACADEMY

By using #BiosimilarMedicines, healthcare professionals have access to a wider spectrum of treatment options and opportunities to change patient treatment pathways for the better. Take for example, biosimilars Infliximab and Adalimumab, used for the treatment of rheumatoid arthritis. Prior to these biosimilars being available, patients had to hit a higher threshold (only those with a more severe condition) and wait longer for access to treatment. Now thanks to biosimilar entry, those with moderate rheumatoid arthritis can also access treatment and improve their condition. Discover more by following #GlobalBiosimilarsWeek! #Biosimilars #RheumatoidArthritis #NHS

Understanding the nuances of treatment response in severe COPD is crucial. Beyond radiological outcomes and lung function improvements, patient perception is paramount. Recent studies suggest a TLVR >50% leads to meaningful outcomes, complemented by exercise capacity and quality of life measures. Let's prioritize holistic patient-centered care in COPD management.

Sub occluding #aortic thrombosis with claudication pain 🔍 In the case of an obese 72-year-old #diabetic patient with dyslipidemia, coronary artery disease, and a history of radical prostatectomy, who presented with bilateral intermittent claudication 👉🏼 41% of survey respondents favored CERAB endo-repair, while 35% preferred endo-repair with an aortic stent. 📊 Let's analyze the treatment chosen by the attending doctors! ➡️ https://ow.ly/Qw5o50S20Yf #PVI #vascular #endovascular